Discuss the implications of making central permission a precondition for state manufacturing licences for antimicrobials, for drug regulation and cooperative federalism.
New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →The Health Ministry's draft G.S.R. 983(E) would add antimicrobials to the "New Drug" definition in Rule 2(1)(w)(v), NDCT Rules, 2019. A manufacturer would then need Central Licensing Authority (CLA) permission before a State Licensing Authority (SLA) can issue a manufacturing licence [1]. This strengthens quality control against AMR, but it also changes the balance between the Centre and the States in a shared area of regulation.
Implications for drug regulation
- Scientific checks before licensing: BA/BE and stability studies become mandatory. This closes a gap where licences were being granted without adequate scrutiny [1].
- Containing AMR: substandard antimicrobials give patients too small a dose, which helps resistant microbes survive. The move fits the One Health commitment in the G20 New Delhi Leaders' Declaration [1].
- One standard everywhere: the same quality benchmark applies in every state instead of differing state practices.
- Capacity concern: in 2012, a Parliamentary Standing Committee found 31 new drugs approved without trials on Indian patients. The Ministry could produce safety reports (PSURs) for only 8 of 42 drugs it was asked about [3]. A central gate only works if CDSCO has enough staff.
- Limits: the check happens once, at licensing, so poor batches made later can still reach the market. Compliance costs and delays may also hit small manufacturers.
Implications for cooperative federalism
- Centralisation: States have traditionally issued manufacturing licences. A central step placed before them shifts effective control to the Centre, and it is being done through delegated legislation rather than an Act of Parliament [1].
- Why the Centre has a case: SLAs licensed many FDCs without DCGI approval even though FDCs were already "new drugs" [2]. The Kokate Committee (2014) review led to a ban on 344 FDCs in 2016, which companies challenged in High Courts [4]. 328 more were banned in 2018 [2], and 16 more, including some antibiotic combinations, in 2026 under Section 26A after a Supreme Court-directed review [5]. A Rajya Sabha committee had earlier found that licensing was not uniform between the Centre and the States [6].
- Layered, not taken over: the SLA still issues the licence [1]. The Centre adds a check before it but does not replace the States, and the 30-day consultation window gives States a voice [1].
Overall, the precondition trades some State autonomy for the same scientific checks everywhere, against a real public-health threat. To work, it needs a stronger CDSCO, a shared Centre–State registry that matches every licence to a prior central permission, and targeted market testing of antimicrobials. Done this way, the measure supports Article 47 and SDG 3 while keeping federalism cooperative.
Sources
- 1Union Health Ministry Proposes Amendment to New Drugs and Clinical Trials Rules, 2019 to Bring Antimicrobials under Central Regulatory Oversight, PIBG.S.R. 983(E), Rule 2(1)(w)(v), CLA→SLA sequence, BA/BE and stability studies, One Health/G20, 30-day window
- 2Prohibition and restriction of manufacture, sale and distribution of Fixed Dose Combinations (FDCs), PIBSLAs licensing FDCs without DCGI approval; 328 FDCs banned in 2018
- 3Lapses in the process of drug approval in India, PRS Legislative Research2012 Standing Committee: 31 drugs approved without Indian trials; PSURs for 8 of 42
- 4Banning of FDC Drugs, PIBKokate Committee; 344 FDCs banned in 2016; High Court challenges
- 5Union Ministry of Health and Family Welfare Prohibits Manufacture, Sale and Distribution of 16 Fixed Dose Combinations (FDCs) in Public Interest, PIB16 FDCs banned under Section 26A after a Supreme Court-directed review, including antibiotic combinations
- 6Rajya Sabha Standing Committee Report on the Drugs and Cosmetics (Amendment) Bill, 2007, via PRSlicensing not uniform between Centre and States